1. Home
  2. BXC vs TECX Comparison

BXC vs TECX Comparison

Compare BXC & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluelinx Holdings Inc.

BXC

Bluelinx Holdings Inc.

HOLD

Current Price

$56.09

Market Cap

587.2M

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$30.50

Market Cap

545.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXC
TECX
Founded
2004
2019
Country
United States
United States
Employees
1700
60
Industry
Wholesale Distributors
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
587.2M
545.3M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
BXC
TECX
Price
$56.09
$30.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$86.00
$75.25
AVG Volume (30 Days)
93.6K
167.5K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
N/A
N/A
Revenue This Year
$5.04
N/A
Revenue Next Year
$5.09
N/A
P/E Ratio
$2,801.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.78
$14.39
52 Week High
$88.30
$35.99

Technical Indicators

Market Signals
Indicator
BXC
TECX
Relative Strength Index (RSI) 51.73 53.42
Support Level $52.71 $17.71
Resistance Level $66.64 $32.27
Average True Range (ATR) 2.44 1.57
MACD 1.21 -0.32
Stochastic Oscillator 87.21 52.58

Price Performance

Historical Comparison
BXC
TECX

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: